Evidence map›Paper›PMID 40838721›Full record

ArticleJournal of virology2025

E2-based mRNA vaccine encapsulated in lipid nanoparticles protects pigs against classical swine fever virus.

Jingyi Liu, Yingju Xia, Chuanwen Tian, Ziyu Chen, Weiqiang Guo, Yingnan Liu, Jing Wen, Zhenhua Xie, Jinzhong Lin, Jiaxin Li and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jingyi Liu *WOAH/National Reference Laboratory for Classical Swine Fever, China Institute of Veterinary Drug Control, Beijing, China.ORCID 0009-0003-9549-0590
Yingju Xia *WOAH/National Reference Laboratory for Classical Swine Fever, China Institute of Veterinary Drug Control, Beijing, China.
Chuanwen TianShanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, China.
Ziyu ChenWOAH/National Reference Laboratory for Classical Swine Fever, China Institute of Veterinary Drug Control, Beijing, China.
Weiqiang GuoShanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, China.
Yingnan LiuShanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, China.
Jing WenState Key Laboratory of Genetic Engineering, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China.
Zhenhua XieShanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, China.
Jinzhong LinState Key Laboratory of Genetic Engineering, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai, China.
Jiaxin LiWOAH/National Reference Laboratory for Classical Swine Fever, China Institute of Veterinary Drug Control, Beijing, China.
Hongjun ChenShanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai, China.ORCID 0000-0002-7254-7596
Yebing LiuWOAH/National Reference Laboratory for Classical Swine Fever, China Institute of Veterinary Drug Control, Beijing, China.

Funding

Central Public-interest Scientific Institution Basal Research Fund Y2022PT11National Key Research and Development Program of China 2022YFD1800500National Key Research and Development Program of China 2023YFD1802600
6 · The paper itself

Abstract

Classical swine fever (CSF), caused by the classical swine fever virus (CSFV), remains a significant threat to the global pig industry. Recent advances in mRNA vaccines offered a promising platform for combating CSFV. In this study, we designed and evaluated three lipid nanoparticle (LNP)-encapsulated mRNA vaccine candidates encoding the ectodomain of E2 glycoprotein (E2_EX), E2_EX fused with the transmembrane (TM) region of the PEDV S protein (E2tm), and E2_EX fused with the TM region of the influenza virus HA protein (E2tm-HA). Among these, the E2tm mRNA vaccine induced the most robust antibody responses in pigs. Immunization of piglets with the E2tm mRNA vaccine showed that its immunogenicity was not impaired by maternal antibodies. Comparative analysis of pseudouridine (Ψ)-modified ( IMPORTANCE: Classical swine fever virus (CSFV) remains a significant threat to the global pig industry. While live attenuated and subunit vaccines are currently in use, there is an urgent need for more effective and safer vaccination strategies. Here, we present a novel mRNA vaccine encoding the CSFV E2 glycoprotein, which provides protective immunity against the CSFV challenge in pigs. Our findings underscore the promising efficacy of this mRNA-based vaccine platform and offer an alternative strategy for CSFV prevention and control.

Indexed as

Classical Swine FeverClassical Swine Fever VirusNanoparticlesViral Envelope ProteinsViral VaccinesAnimalsAntibodies, ViralLipidsLiposomesmRNA VaccinesRNA, MessengerSwineVaccinationVaccines, SyntheticAntibodies, Viralglycoprotein E2, classical swine fever virusLipid NanoparticlesLipidsLiposomesmRNA VaccinesRNA, MessengerVaccines, SyntheticViral Envelope ProteinsViral VaccinesCSFVE2 proteinmRNA vaccineprotective immunity

Identifiers

PMID40838721
PMCPMC12456140

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.